$6.385
-0.536 (-8.39%)At close
NVNO Profitability and Margins
Evaluating the bottom line, enVVeno Medical Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.11%, provide a clear picture of how effectively NVNO converts its operational activities into shareholder value.
NVNO Comparative Benchmarking
In the context of the broader market, NVNO competes directly with industry leaders such as WOK and CDIO. With a market capitalization of $4.44M, it holds a significant position in the sector. When comparing efficiency, NVNO's gross margin of N/A stands against WOK's 19.14% and CDIO's 100.00%. Such benchmarking helps identify whether enVVeno Medical Corp is trading at a premium or discount relative to its financial performance.
enVVeno Medical Corp Financial Performance
The company has consistently reported negative net income, with the latest quarterly loss at -$6.29 per share and a forward P/E ratio of 0, indicating no earnings expected in the near term.
Financials
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.